ALD 601

Drug Profile

ALD 601

Alternative Names: ALD-601

Latest Information Update: 12 Apr 2017

Price : $50

At a glance

  • Originator Aldagen
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Lysosomal storage diseases

Most Recent Events

  • 03 Apr 2017 Aldagen withdrew a phase I trial prior to enrolment for Lysosomal storage diseases as patients were consented to screening but none were enrolled and proceeded with transplant in USA (Parenteral) (NCT01003912)
  • 05 May 2014 Discontinued - Phase-I for Lysosomal storage diseases in USA (Parenteral)
  • 08 Feb 2012 Aldagen has been acquired by Cytomedix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top